MX2017013886A - Azabenzimidazoles y su uso como moduladores del receptor ampa. - Google Patents

Azabenzimidazoles y su uso como moduladores del receptor ampa.

Info

Publication number
MX2017013886A
MX2017013886A MX2017013886A MX2017013886A MX2017013886A MX 2017013886 A MX2017013886 A MX 2017013886A MX 2017013886 A MX2017013886 A MX 2017013886A MX 2017013886 A MX2017013886 A MX 2017013886A MX 2017013886 A MX2017013886 A MX 2017013886A
Authority
MX
Mexico
Prior art keywords
azabenzimidazoles
receptor modulators
ampa receptor
formula
compounds
Prior art date
Application number
MX2017013886A
Other languages
English (en)
Inventor
Devin M Swanson
Chen Gang
Zhang Wei
Ravula Suchitra
M Savall Bradley
K Ameriks Michael
G B Berry Cynthia
Loic Jourdan Fabrice
Patrick Lebold Terry
Wei LIN David
Wu Dongpei
Angel Pena Piñón Miguel
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2017013886A publication Critical patent/MX2017013886A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En la presente invención se proporcionan compuestos de la Fórmula (I) y sales farmacéuticamente aceptables, N-óxidos o solvatos de estos; (ver Fórmula) además, se proporcionan en la presente invención composiciones farmacéuticas que comprenden compuestos de la Fórmula (I) y métodos para usar los compuestos de la Fórmula (I).
MX2017013886A 2015-04-29 2016-04-28 Azabenzimidazoles y su uso como moduladores del receptor ampa. MX2017013886A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154313P 2015-04-29 2015-04-29
PCT/US2016/029801 WO2016176460A1 (en) 2015-04-29 2016-04-28 Azabenzimidazoles and their use as ampa receptor modulators

Publications (1)

Publication Number Publication Date
MX2017013886A true MX2017013886A (es) 2018-03-12

Family

ID=56008859

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013886A MX2017013886A (es) 2015-04-29 2016-04-28 Azabenzimidazoles y su uso como moduladores del receptor ampa.

Country Status (39)

Country Link
US (4) US11312712B2 (es)
EP (3) EP3288940B9 (es)
JP (2) JP6800886B2 (es)
KR (2) KR20240017991A (es)
CN (1) CN107835814B (es)
AR (1) AR104447A1 (es)
AU (2) AU2016255434C1 (es)
BR (2) BR122023023802A2 (es)
CA (1) CA2983826A1 (es)
CO (1) CO2017011017A2 (es)
CR (1) CR20170484A (es)
CY (1) CY1124059T1 (es)
DK (1) DK3288940T5 (es)
EA (1) EA033281B1 (es)
EC (1) ECSP17074645A (es)
ES (1) ES2865330T3 (es)
GT (1) GT201700231A (es)
HK (1) HK1252249A1 (es)
HR (1) HRP20210403T1 (es)
HU (1) HUE053943T2 (es)
IL (1) IL254848B (es)
JO (1) JO3654B1 (es)
LT (1) LT3288940T (es)
MA (1) MA41988B1 (es)
MD (1) MD3288940T2 (es)
MX (1) MX2017013886A (es)
MY (1) MY194104A (es)
NI (1) NI201700129A (es)
PH (1) PH12017501816A1 (es)
PL (1) PL3288940T3 (es)
PT (1) PT3288940T (es)
RS (1) RS61688B1 (es)
SG (1) SG11201708190UA (es)
SI (1) SI3288940T1 (es)
TW (1) TWI706952B (es)
UA (1) UA120304C2 (es)
UY (1) UY36654A (es)
WO (1) WO2016176460A1 (es)
ZA (1) ZA201708065B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10513523B2 (en) * 2015-04-29 2019-12-24 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators
CN107383004B (zh) * 2017-07-05 2020-04-17 浙江大学 2-氨基咪唑并吡啶类衍生物及制备和应用
WO2019043217A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROBENZIMIDAZOLONES
US11447488B2 (en) 2017-10-06 2022-09-20 Takeda Pharmaceutical Company Limited Heterocyclic compounds
BR112021006488A2 (pt) 2018-10-05 2021-07-06 Annapurna Bio Inc compostos e composições para o tratamento de condições associadas com atividade do receptor apj
WO2020087170A1 (en) * 2018-10-30 2020-05-07 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
AU2020317381A1 (en) * 2019-07-22 2022-02-10 Repare Therapeutics Inc. Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors
EP4263523A2 (en) * 2020-12-16 2023-10-25 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN114591338B (zh) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途
CN115304599A (zh) * 2022-09-20 2022-11-08 浙大宁波理工学院 一种3-溴-6-异丙基-1氢-哌咯[2，3-b]并吡啶及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
CN1051313A (zh) 1990-11-07 1991-05-15 鞍山市振东工业尼龙厂 尼龙球磨罐及其热装工艺
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
TW251284B (es) 1992-11-02 1995-07-11 Pfizer
CN1067386C (zh) 1994-02-10 2001-06-20 辉瑞大药厂 作为苯并二氮杂䓬受体位的兴奋剂和拮抗药的5－杂芳基吲哚衍生物
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
UA54403C2 (uk) 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
JP2002519373A (ja) 1998-07-02 2002-07-02 エーザイ株式会社 製薬組成物及びそれらの使用
BR9916735A (pt) 1998-12-31 2001-09-25 Sugen Inc Compostos de 3-heteroarilidenil-2-indolinona para a modulação da atividade das cinases protéicas e para uso na quimioterapia do cancêr
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
AU2001282865A1 (en) 2000-08-11 2002-02-25 Eli Lilly And Company Heterocyclic sulfonamide derivatives
US6548576B1 (en) 2001-11-07 2003-04-15 Bourns, Inc. Epoxy formulation adapted to be used in conjunction with no-lead solder in electronic components
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
EP1786812B1 (en) * 2004-09-03 2011-11-09 Merck Serono SA Pyridine methylene azolidinones and their use as phosphoinositide inhibitors
UA101299C2 (uk) 2005-09-30 2013-03-25 Глаксо Груп Лімітед Сполуки, що мають активність стосовно рецепторів м1, та їх застосування в медицині
WO2007135529A2 (en) 2006-05-23 2007-11-29 Pfizer Products Inc. Azabenzimidazolyl compounds as mglur2 potentiators
WO2008053031A1 (en) 2006-11-03 2008-05-08 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
WO2008113795A1 (en) 2007-03-20 2008-09-25 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
GB0711089D0 (en) 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009067607A2 (en) 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
JP2011506335A (ja) 2007-12-06 2011-03-03 シェーリング コーポレイション γ−セクレターゼ調節剤
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
US20110312938A1 (en) * 2008-06-30 2011-12-22 Ironwood Pharmaceuticals, Inc. Pyrrolopyridine Carboxylic Acid Derivatives
GB0822425D0 (en) 2008-12-09 2009-01-14 Glaxo Group Ltd Compounds
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
EP2579717A4 (en) * 2010-06-09 2013-12-11 Merck Sharp & Dohme POSITIVE ALLOSTERIC MODULATORS OF MGLUR2
CN103180326B (zh) 2010-08-10 2015-06-10 武田药品工业株式会社 杂环化合物及其用途
US8993779B2 (en) 2010-08-12 2015-03-31 Merck Sharp & Dohme Corp. Positive allosteric modulators of MGLUR2
US9481677B2 (en) 2011-10-31 2016-11-01 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
WO2013130501A1 (en) 2012-03-01 2013-09-06 The Board Of Regents Of The University Of Texas System Bivalent ampa receptor positive allosteric modulators
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
JO3225B1 (ar) 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
CN105121439A (zh) 2013-02-19 2015-12-02 辉瑞公司 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物

Also Published As

Publication number Publication date
PT3288940T (pt) 2021-04-30
US20230110576A1 (en) 2023-04-13
TWI706952B (zh) 2020-10-11
EA201792374A1 (ru) 2018-05-31
DK3288940T5 (da) 2021-09-20
US20180118740A1 (en) 2018-05-03
EP3288940A1 (en) 2018-03-07
JP7026194B2 (ja) 2022-02-25
MA41988A (fr) 2018-07-03
MY194104A (en) 2022-11-11
AU2020210231A1 (en) 2020-08-20
CA2983826A1 (en) 2016-11-03
MD3288940T2 (ro) 2021-08-31
PH12017501816A1 (en) 2018-04-23
CN107835814B (zh) 2021-07-23
MA41988B1 (fr) 2021-03-31
SG11201708190UA (en) 2017-11-29
NZ736057A (en) 2023-08-25
AU2020210231B2 (en) 2021-07-22
AU2016255434B2 (en) 2020-05-14
EA033281B1 (ru) 2019-09-30
AU2016255434C1 (en) 2021-09-23
HRP20210403T1 (hr) 2021-10-29
LT3288940T (lt) 2021-05-10
SI3288940T1 (sl) 2021-07-30
KR20240017991A (ko) 2024-02-08
JP2021042230A (ja) 2021-03-18
KR20170140382A (ko) 2017-12-20
EP3288940B9 (en) 2021-07-21
AU2016255434A1 (en) 2017-10-26
GT201700231A (es) 2018-12-20
EP4144736A1 (en) 2023-03-08
IL254848A0 (en) 2017-12-31
TW201708217A (zh) 2017-03-01
BR122023023802A2 (pt) 2023-12-26
DK3288940T3 (da) 2021-05-25
ES2865330T3 (es) 2021-10-15
HUE053943T2 (hu) 2021-08-30
US11312712B2 (en) 2022-04-26
NI201700129A (es) 2019-05-10
ZA201708065B (en) 2019-09-25
CN107835814A (zh) 2018-03-23
JP2018518462A (ja) 2018-07-12
JO3654B1 (ar) 2020-08-27
WO2016176460A1 (en) 2016-11-03
BR112017023147B1 (pt) 2024-04-30
US20210284641A1 (en) 2021-09-16
CR20170484A (es) 2018-02-26
IL254848B (en) 2021-01-31
JP6800886B2 (ja) 2020-12-16
BR112017023147A2 (pt) 2018-07-10
EP3901153A1 (en) 2021-10-27
US20230114165A1 (en) 2023-04-13
UA120304C2 (uk) 2019-11-11
ECSP17074645A (es) 2018-02-28
HK1252249A1 (zh) 2019-05-24
CY1124059T1 (el) 2022-05-27
CO2017011017A2 (es) 2018-03-20
UY36654A (es) 2016-10-31
EP3288940B1 (en) 2021-02-24
RS61688B1 (sr) 2021-05-31
PL3288940T3 (pl) 2021-07-12
AR104447A1 (es) 2017-07-19

Similar Documents

Publication Publication Date Title
MX2017013886A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa.
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
MX2020003532A (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrogenos y usos de los mismos.
MX2018011831A (es) Antagonistas solubles de receptor de c5aa(c5ar).
MX2017008520A (es) Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MX2016009403A (es) Compuestos heterociclicos.
MX2017013877A (es) Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
PH12017500732A1 (en) Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine
PH12016501624A1 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
PH12019501639A1 (en) Jaki selective inhibitors
ZA201903291B (en) Fused bicylic pyridine compounds and their use as ampa receptor modulators
TN2017000384A1 (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors.
MY186475A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
MX369806B (es) Compuestos de indolona y su uso como moduladores del receptor ampa.
EA201991045A1 (ru) Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора

Legal Events

Date Code Title Description
FG Grant or registration